Interferon-gamma release assay clarifi es the effect of bacille calmette-Guérin vaccination in Greek army recruits

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 5, 2010, Pages 545-550

  Katsenos, S ^a   Nikolopoulou, M ^a   Konstantinidis, A K ^a   Gartzonika, C ^a   Gogali, A ^a   Margelis, I ^a   Tatsioni, A ^a   Mavridis, A ^a   Constantopoulos, S H ^a   Daskalopoulos, G ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

BCG; IGRA; Latent tuberculosis infection; Quanti FERON; Tuberculin skin test

Indexed keywords

BCG VACCINE;

ADULT; ARMY; ARTICLE; ASSAY; BCG VACCINATION; CONTROLLED STUDY; FEMALE; GREECE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; SKIN INDURATION; TUBERCULIN TEST;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; BCG VACCINE; CROSS-SECTIONAL STUDIES; FEMALE; GREECE; HUMANS; INTERFERON-GAMMA; MALE; MILITARY PERSONNEL; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 77950899095     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354. (Pubitemid 351650594)
2. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204. (Pubitemid 44713473)
3. Fine P E M. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989; 11: S353-S359.
4. Cook V, Fitzgerald J M, Menzies D. Clinical interpretation of tests for latent tuberculosis infection. In: Davies P D O, Barnes P F, Gordon S B, eds. Clinical tuberculosis. London, UK: Hod-der Arnold, 2008: pp 393-410.
5. Wang L, Turner M O, Elwood R K, et al. A meta-analysis of the effect of bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804-809. (Pubitemid 34984980)
6. World Health Organization. Expanded program on immunization. Immunization schedules in the WHO European Region 1995. Wkly Epidemiol Rec 1995; 70: 221-228.
7. Theodoracopoulos P, Dimadi M, Constantopoulos S H. Calculation of new cases of tuberculosis from the consumption of anti-tuberculosis medications: comparison with notif cation rates. Respiration 1992; 59: 64.
8. World Health Organization. Global tuberculosis control: surveillance, planning, f nancing. WHO report 2006. WHO/HTM/TB/2006.362. Geneva, Switzerland. http://www.who. int/tb/publications/global-report/2006/en/index.html Accessed April 2009.
9. Kang Y, Lee W H, Yoan H I, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756-2761.
10. Harada N, Nakajima Y, Higuchi K, et al. Screening for tuberculosis infection using whole-blood interferon-gamma and Man-toux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006; 27: 442-448. (Pubitemid 43835524)
11. Connell T G, Curtis N, Ranganathan S G, et al. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 2006; 61: 616-620 (Pubitemid 44035143)
12. ®-TB Gold (In-Tube method)\package insert. Carnegie, VIC, Australia: Cellestis, 2006. http://www.cellestis.com/IRM/Company/ShowPage.aspx.?CPID= 1023 Accessed August 2007.
13. Mazurek G H, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005; 54: 49-55.
14. National Institute for Health and Clinical Excellence. Clinical guideline 33. Preventing and treating tuberculosis. London, UK: NICE, 2006. http://www.nice.org.uk/nicemedia/pdf/CG033 publicinfo.pdf Accessed March 2010.
15. Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008; 34: 1-13.
16. van Zyl-Smit R, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-γ responses after tuberculin skin testing. Am J Respir Crit Care Med 2009; 180: 49-58.
17. Mazurek G H, Zajdowicz M J, Hankinson A L, et al. Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis 2007; 45: 826-836.
18. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
19. Menzies D. What does tuberculin reactivity after bacille Cal-mette-Guerin vaccination tell us? Clin Infect Dis 2000; 31 (Suppl 3): S71-S74. (Pubitemid 32269592)
20. Dascalopoulos G, Constantopoulos S H. Tuberculin sensitivity after successful BCG vaccination [Abstract]. Eur Respir J 1989; 2: S756.
21. Diel R, Nienhaus A, Lange C, et al. Tuberculosis contact investigation with a new, specif c blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006; 7: 77. (Pubitemid 43959902)
22. Lee S S, Liu Y C, Huang T S, et al. Comparison of the interferon-gamma release assay and the tuberculin skin test for contact investigation of tuberculosis in BCG-vaccinated health care workers. Scand J Infect Dis 2008; 40: 373-380.
23. Haverkamp M H, Arend S M, Lindeboom J A, et al. Nontuber-culous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis 2004; 39: 450-456.
24. von Reyn C F, Horsburgh C R, Olivier K N, et al. Skin test reactions to Mycobacterium tuberculosis purif ed protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5: 1122-1128.
25. Dascalopoulos G, Loukas S, Constantopoulos S H. Wide geographic variations of sensitivity to MOTT sensitins in Greece. Eur Respir J 1995; 5: 715-717.
26. Detjen A K, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45: 322-328. (Pubitemid 47101028)
27. Pollock N R, Campos-Neto A, Kashino S, et al. Discordant QuantiFERON-TB Gold test results among US healthcare workers with increased risk of latent tuberculosis infection: a problem or solution? Infect Control Hosp Epidemiol 2008; 29: 878-886.
28. Hill P C, Brookes R H, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38: 966-973. (Pubitemid 38457204)
29. Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specif c blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170: 65-69. (Pubitemid 38997753)
30. Pai M, Gokhale K, Joshi R, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005; 293: 2756-2785. (Pubitemid 40973379)
31. Hill P C, Brookes R H, Fox A, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007; 4: e192. (Pubitemid 46998623)
32. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006; 174: 349-355. (Pubitemid 44156616)
33. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T-cell assay conversions and reversions? PLoS Med 2007; 4: e208. (Pubitemid 46998611)
34. Salpeter S R. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159: 560-564.
35. Leung C C, Chang K C. Role of interferon gamma release assays in tuberculosis. Respirology 2009; 14: 156-158.